Steven Deitelzweig
Overview
Explore the profile of Steven Deitelzweig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atreja N, Dubey A, Kang A, Jiang J, Hagan M, Michael-Asalu A, et al.
Adv Ther
. 2025 Jan;
42(3):1462-1483.
PMID: 39883308
Introduction: Atrial fibrillation (AF), a common heart rhythm abnormality, is linked to a higher risk of stroke. Traditionally, warfarin has been the primary anticoagulation treatment for reducing the stroke risk....
2.
Lip G, Noxon V, Kang A, Luo X, Atreja N, Han S, et al.
J Thromb Thrombolysis
. 2024 May;
57(6):1092-1102.
PMID: 38698197
Introduction: There is a paucity of real-world studies examining the risks of stroke/systemic embolism (SE) and major bleeding (MB) among non-valvular atrial fibrillation (NVAF) patients switching from warfarin to a...
3.
Deitelzweig S, Kang A, Jiang J, Gao C, Luo X, Atreja N, et al.
J Clin Med
. 2024 Feb;
13(4).
PMID: 38398386
Background: Real-world evidence on direct oral anticoagulant outcomes among Non-Valvular Atrial Fibrillation (NVAF) patients is limited. We aimed to evaluate stroke/systemic embolism (SE) and major bleeding (MB) risks among NVAF...
4.
Deitelzweig S, Xie L, Terasawa E, Hood D, Cato M, Atreja N, et al.
Am J Manag Care
. 2023 Nov;
29(11):e330-e338.
PMID: 37948653
Objectives: To investigate the journey to oral anticoagulant (OAC) access following formulary-related rejection of apixaban (Eliquis) and evaluate characteristics associated with failure to achieve OAC access among patients with atrial...
5.
Deitelzweig S, Terasawa E, Atreja N, Kang A, Hines D, Dhamane A, et al.
Curr Med Res Opin
. 2023 Jul;
39(8):1093-1101.
PMID: 37519272
Objective: To assess potential impacts of formulary tier increases of apixaban-an efficacious oral anticoagulant (OAC) for preventing stroke in patients with atrial fibrillation (AF)-on patients' prescription drug plan (PDP) switching...
6.
Deitelzweig S, Keshishian A, Kang A, Jenkins A, Atreja N, Schuler P, et al.
Eur J Intern Med
. 2022 Dec;
108:37-42.
PMID: 36456387
Background: Oral anticoagulants (OACs) mitigate stroke and systemic embolism (SE) risk in non-valvular atrial fibrillation (AF) patients but can increase the risk of major bleeding (MB). This study analyzed the...
7.
Deitelzweig S, Terasawa E, Kang A, Atreja N, Hines D, Noman A, et al.
Curr Med Res Opin
. 2022 Sep;
38(11):1885-1890.
PMID: 36164763
In recent years, US payers have increased usage of formulary exclusions as a means to help manage costs. Earlier this year, one of the largest pharmacy benefit managers in the...
8.
Lip G, Murphy R, Sahiar F, Ingall T, Dhamane A, Ferri M, et al.
JAMA Netw Open
. 2022 Aug;
5(8):e2229333.
PMID: 36044214
Importance: The CHA2DS2-VASc score (calculated as congestive heart failure, hypertension, age 75 years and older, diabetes, stroke or TIA, vascular disease, age 65 to 74 years, and sex category) is...
9.
Deitelzweig S, Zhu J, Jiang J, Luo X, Keshishian A, Ferri M, et al.
Curr Med Res Opin
. 2022 Aug;
38(11):1891-1896.
PMID: 36000258
Introduction: This study evaluated the risk of hospitalization among nonvalvular atrial fibrillation (NVAF) patients with an outpatient COVID-19 diagnosis who discontinued vs continued apixaban treatment. Methods: Adult patients with NVAF...
10.
Lip G, Keshishian A, Kang A, Luo X, Atreja N, Zhang Y, et al.
J Thromb Thrombolysis
. 2022 May;
54(1):33-46.
PMID: 35579733
Introduction: There are a paucity of real-world data examining effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial fibrillation (NVAF) patients with prior bleeding....